Castle Biosciences (CSTL) Capital Expenditures (2018 - 2026)

Castle Biosciences has reported Capital Expenditures for 9 years, with the latest figure at $8.6 million in Q2 2026.

• Quarterly Capital Expenditures fell 6.62% year-over-year to $8.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $43.1 million (up 54.3% YoY) and the FY2025 annual result came in at $36.0 million, up 27.17% from the prior year.
• Capital Expenditures fell to $8.6 million in Q2 2026 per CSTL's latest filing, from $12.5 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $14.8 million in Q3 2025 and troughed at $402000.0 in Q1 2022.
• A 5-year average of $5.8 million and a median of $5.0 million in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures plunged 95.67% in 2022, then soared 730.35% in 2023.
• Over 5 years, Capital Expenditures stood at $1.8 million in 2022, then jumped by 112.26% to $3.8 million in 2023, then soared by 99.5% to $7.6 million in 2024, then decreased by 5.06% to $7.2 million in 2025, then gained by 20.41% to $8.6 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $8.6 million, $12.5 million, and $7.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.